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Relative survival of patients diagnosed with cancers of the colorectum, lung and female breast from Yorkshire, UK and New South
Wales (NSW), Australia in 1992–2000 were compared using multiple regression models to adjust for various factors. Statistically
significant differences were observed for all sites, Yorkshire patients having a 47–58% higher risk of excess death than those of NSW.
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UK cancer survival rates have been reported to be inferior to those
from many other European countries for most of the common
cancer types (Sant et al, 2003). The EUROCARE data, on which
such reports have been based, have been criticised from several
perspectives (Cookson, 2000; Woodman et al, 2001), among which
have been concerns that the processes of cancer registration have
not been strictly comparable. Cancer registration and mortality
notification systems are directly comparable in the UK and
Australia, and routine published survival data show substantial
differences between the two countries with outcomes generally
being worse in the UK (Australian Institute of Health and Welfare
(AIHW) and Australasian Association of Cancer Registries, 2001;
National Statistics, 2002).
Routine cancer survival rates can, however, be difficult to
compare due to variation in the methodological and statistical
approaches used. We have compared, therefore, survival rates for
three common cancers (colorectal, lung and female breast) in
Yorkshire, UK and New South Wales (NSW), Australia using
identical methodology in an analysis of individual patient data for
cases diagnosed from 1992 to 2000. The cancer registries providing
the data (the Northern and Yorkshire Cancer Registry and
Information Service – NYCRIS and the NSW Central Cancer
Registry – NSWCCR) are population based, have been operational
for several decades and have high standards of data completeness,
quality and follow-up. The population sizes for the two registries
are large: 3.6 million for the Yorkshire data within NYCRIS and 6.5
million for NSWCCR, and rates of cancer survival in the registry
populations are similar to the corresponding national rates for the
UK and Australia.
MATERIALS AND METHODS
Data sets with individual patient records were provided by
NYCRIS and NSWCCR for all new diagnoses of cancer of the
colorectum, lung and female breast during the time period 1992–
2000. Follow-up for death was complete in both registries until 31
December 2001. Only first occurrences of primary cancer for
individuals aged 15–89 years at diagnosis were included. Cases
notified by death certificate only, identified at postmortem or with
a survival time equal to zero (diagnosed and died on the same
day), were excluded from analyses.
A modification of the period method (Brenner and Gefeller,
1996) was used to compute 5-year relative survival ratios (RSR)
of cancers diagnosed in the period 1992–2000 and deaths 1996
to 2001. Survival time was measured from the month of
diagnosis to the date of death, or in the period at the end of
2001. The period method focuses on a recent time interval
(1996–2001) in ensuring which each patient’s survival experi-
ence is observed and excludes short-term survival of patients
diagnosed before the start of the interval (diagnosed 1992–1995
and dying before 1996) but includes their long-term survival
within the period. Short-term survival of more recently
diagnosed patients (those diagnosed between 1996 and 2000)
was included. Observed and expected survival were estimated
using standard life table methods (Voutilainen et al, 2000). Life
tables for the relevant populations were obtained from the
(England and Wales) Office for National Statistics for the
Yorkshire and Humber Region (1998) and from the Australian
Bureau of Statistics for NSW (1996–2000). A 5-year cumulative
RSR was calculated as the ratio of the cumulative observed
survival to the cumulative expected survival, with 95%
confidence intervals (CI) calculated using the complementary
log–log transformation (Voutilainen et al, 2000). Age-standar-
dised RSR were calculated using the EUROCARE method
(Berrino et al, 1995) and the corresponding 95% CI were
computed using a logistic transformation.
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of death during the first 5 years was constructed for each type
of cancer, which included age group (15–44, 45–59, 60–74 and
75–89 years), years since diagnosis, sex (for lung and colorectal
cancers) and place of residence (Yorkshire/NSW) as the main
effects, and the interaction between age group and years since
diagnosis to allow for nonproportional hazards across years of
follow-up. The relative excess risk (RER) of death for each cancer
type for Yorkshire was defined as the ratio of the excess risk of
death in Yorkshire to that in NSW. The RER and its 95% CI were
calculated using the estimated coefficients and standard errors
from the Poisson model. The effect of place of residence on the
excess risk of death was tested using the likelihood ratio statistic
with Po0.01 indicating statistical significance.
RESULTS
Table 1 shows, for each site of cancer, the number of cases
included in the analysis, observed and relative 5-year survival and
age-standardised 5-year RSR in the two populations, together with
RER of death due to cancer for Yorkshire relative to NSW.
Statistically significant differences in 5-year RSR were found for all
three types of cancer with NSW patients consistently having better
outcomes. There were benefits in RSR after age standardisation of
more than 5% for lung and female breast cancers and of almost
10% for colorectal cancer. Statistically significant differences
(Po0.0001) in survival for all three cancer types were observed
after adjustment for age, sex and years since diagnosis with the
RER of death being 47–58% higher in Yorkshire patients.
DISCUSSION
This study has shown moderate but important differences in
cancer survival between the UK and Australia. For all three
cancers, colorectal, lung and female breast, the 5-year survival
rates were lower in the UK population with a statistically
significant RER of death of around 50%. The rates were based
on substantial numbers of cases and deaths and represent cancers
with relatively good (breast), moderate (colorectal) and poor
(lung) prognoses. We have used identical statistical methodology
to analyse the two data sets and age-adjusted comparisons to
control for the younger age structure of the Australian population.
Both NYCRIS and NSWCCR fulfil the requirements of a mature
cancer registry (Woodman et al, 2001): total population coverage,
with notifications from multiple sources to maximise case
ascertainment, and efficient and regular linkage to death
certificates. We believe, therefore, that the data quality and
processes of registration of the two registries are similar and
comparable and that the observed differences in survival cannot
readily be attributed to variations in the validity of the registry
data. In neither population was there any systematic screening for
colorectal or lung cancers during 1992–2000 and both populations
had similar levels of breast cancer screening. In Yorkshire, 75.2%
of women aged 50–64 years accept first invitations to screening
(86.9% after initial screen), with 4.9 cancers detected per 1000
women screened (NHSBSP, 2003), whereas in NSW initial screen-
ing rates are 66.8% (80.1% for subsequent screen) for women aged
50–69 years, with 5.4 cancers detected per 1000 women (Estoesta
et al, 2000). Intensity of screening activity is, therefore, unlikely to
be an explanation for the differences.
The most recently published EUROCARE results (Sant et al,
2003) cover an earlier time period (1990–1994) than that considered
here, but it is worth noting that the survival differences between
Yorkshire and NSW that we have reported are broadly similar to
those between England and the European weighted mean reported
in EUROCARE. As with EUROCARE, the differences in survival
between the populations may represent differences in access to, and
quality of care delivered, earlier diagnosis, or a combination of these
variables. These factors can only be disentangled by more detailed
studies that consider both the stage of disease at presentation and
the treatment received after diagnosis.
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Table 1 The 5-year observed and RSR, age-standardised 5-year RSR and RER of death for three major cancers in Yorkshire, UK and NSW, Australia,
patients diagnosed in 1992–2000 and with mortality in 1996–2001
Number of new
cases
5-year observed
survival (%) 5-year RSR (%) with (95% CI)
Age-standardised 5-year RSR
(%) with (95% CI)
Cancer
type Yorkshire NSW Yorkshire NSW Yorkshire NSW Yorkshire NSW
RER
a for
Yorkshire (95%
CI)
Colorectal 16710 27801 38.3 52.5 49.3 (48.2–50.4) 60.5 (59.7–61.3) 50.3 (48.4–52.2) 60.1 (58.9–61.3) 1.47 (1.42–1.53)
Lung 15864 14816 5.6 12.1 6.9 (6.4–7.3) 13.8 (13.2–14.4) 7.7 (5.9–9.9) 13.1 (11.4–15.0) 1.49 (1.45–1.53)
Breast (F) 20338 28684 68.9 79.6 77.2 (76.3–78.1) 84.9 (84.3–85.5) 78.2 (77.0–79.3) 84.5 (83.8–85.3) 1.58 (1.48–1.68)
RSR¼relative survival ratios; RER¼relative excess risk; 95% CI¼95% confidence interval.
aAdjusted for age at diagnosis, sex, years since diagnosis and interaction of age and
years since diagnosis in a Poisson regression model.
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